Home/Pipeline/Bimekizumab (Bimzelx)

Bimekizumab (Bimzelx)

Psoriatic Arthritis

ApprovedCommercial

Key Facts

Indication

Psoriatic Arthritis

Phase

Approved

Status

Commercial

Company

UCB

About UCB

UCB S.A. is a multinational biopharmaceutical company founded in 1928, originally as Union Chimique Belge. The company has evolved from a diversified chemical company into a focused biopharmaceutical leader with approximately 8,500 employees worldwide. UCB concentrates on patient solutions in neurology and immunology, with a strong portfolio of approved medicines including Keppra for epilepsy, Cimzia for inflammatory diseases, and Vimpat for seizure disorders.

View full company profile

Therapeutic Areas

Neurology Immunology Epilepsy Parkinson's Disease Multiple Sclerosis Rheumatoid Arthritis Psoriasis Inflammatory Diseases

Other Psoriatic Arthritis Drugs

Drug	Company	Phase	Status
Icotrokinra (JNJ-2113)	Protagonist Therapeutics	Phase 3	ICONIC PsA-1 & -2 ongoing
Zunsemetinib (ATI-450)	Aclaris Therapeutics	Phase 2b	Active